Dyslipidemia is a disruption in the amount of lipids in the blood.
Treatment with life-saving medications has increased over the past ten years in ischaemic heart disease but levels are still suboptimal, according to the first results of the Chronic Ischaemic Cardiovascular Disease (CICD) Pilot Registry presented today at ESC Congress 2015 and published in European Heart Journal.
Amgen today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London.
If you are watching what you eat, working out, and still not seeing improvements in your cholesterol, blood pressure, blood sugar, etc., here's some hope. A new report appearing in the August 2015 issue of The FASEB Journal suggests that inflammation induced by deficiencies in vitamins and minerals might be the culprit.
Resistance training in the gym leads to a fall in liver fat levels. This is the finding of a new study held at the University of Haifa in cooperation with Tel Aviv Medical Center and Tel Aviv University.
Scientists from the Florida campus of The Scripps Research Institute have been awarded nearly $1.5 million from the National Institute of General Medical Sciences of the National Institutes of Health to explore the therapeutic potential of a class of proteins that play essential roles in the regulation and maintenance of human health.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Praluent (alirocumab), recommending its approval for use in certain adult patients with hypercholesterolemia.
End-stage renal disease (ERSD) is the last stage of chronic kidney disease where the kidneys function at under 10 to 15 percent of their normal capacity. At this stage, kidneys cannot effectively remove waste or excess fluid from the blood system, and dialysis or a kidney transplant is necessary to live.
The National Institute for Health and Care Excellence has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.
Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS).
A new study suggests that genes may not be to blame for the increased risk of heart disease some studies have shown in people with migraine, especially those with migraine with aura. The research is published during Headache/Migraine Awareness Month in the inaugural issue of the journal Neurology Genetics, an open access, or free to the public, online-only, peer-reviewed journal from the American Academy of Neurology.
A controlled study published in the current issue of Psychotherapy and Psychosomatic indicates the usefulness of a brief behavioral intervention targeting psychological risk factors for vascular disease.
Obesity is caused by numerous and complex factors, some of which are as yet unsuspected. Scientists from the CNRS, INSERM, UPMC and Université Paris Descartes, working with research clinicians from Paris Public Hospitals (AP-HP) have now shown that severe obesity is accompanied by inflammation of the small intestine and enhanced immune response in that region.
Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).
Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015.
Patients with rheumatoid arthritis are at increased risk of a surprise heart attack, according to new research presented today at ICNC 12 by Dr Adriana Puente, a cardiologist in the National Medical Centre "20 de Noviembre" ISSSTE in Mexico City, Mexico.
While testosterone replacement therapies may be controversial in males, new research in The FASEB Journal may extend this controversy to females too. That's because research involving mice, appearing in the April 2015 issue, suggests that there is an association between low levels of androgens (which includes testosterone), and atherosclerosis and obesity in females.
Nektar Therapeutics reported that partner AstraZeneca announced today that MOVANTIK (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.
Amgen today announced that an application seeking marketing approval of Repatha (evolocumab) for the treatment of high cholesterol has been submitted for review to the Ministry of Health, Labour and Welfare in Japan.
Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions.
Obesity guidelines recommend an initial weight loss goal of 5 to 10% of start weight to improve health. A recent study found that patients who received liraglutide 3.0 mg, combined with fewer calories and more physical activity, were more than twice as likely to achieve at least that level of weight loss, compared to patients on placebo who made similar lifestyle changes.